Humana announces extraordinary shareholder meeting
Bitget2026/10/06 10:25Humana will hold an extraordinary general meeting in Stockholm on Oct. 30, 2026. Ambea, which controls more than 90% of shares and votes, has requested the meeting. Shareholders will vote on setting the board at three members, with no board remuneration. Mark Jensen, Benno Eliasson, Johan Regnér are proposed as new board members; Jensen is proposed as chair. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humana AB published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Humana will hold an extraordinary general meeting in Stockholm on Oct. 30, 2026.
- Ambea, which controls more than 90% of shares and votes, has requested the meeting.
- Shareholders will vote on setting the board at three members, with no board remuneration.
- Mark Jensen, Benno Eliasson, Johan Regnér are proposed as new board members; Jensen is proposed as chair.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
